跳至主要内容
临床试验/DRKS00017497
DRKS00017497招募中2 期

A multicenter randomized, controlled, double-blinded trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis - Generate-Boost

Friedrich-Schiller-Universität Jena0 个研究点目标入组 50 人开始时间: 2019年11月12日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Clinical diagnosed severe autoimmune encephalitis (mRS = 3)
  • auto-antibodies against neuronal surface proteins in the liquor or serum, proof not older than 4 weeks prior to randomisation
  • pretreatment with Rituximab
  • Age =18 Jahre
  • signed informed consent
  • women of childbearing potential (up to 2 years after menopause): negative pregnancy test

排除标准

  • breast-feeding
  • acute infiltrative pulmonary disease
  • acute infiltrative pericardial disease
  • malignant tumor and current chemotherapy
  • current participation in another interventional study
  • previous participation in this study
  • known hypersensitivity to an ingredient of the investigational product
  • continued therapy with glucocorticoids / Rituximab during the study (last administration must be prior to the first dose of the investigational product)

研究者

相似试验